Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02040558 · ClinicalTrials.gov registry record · Phase 1
Trial to Study the Safety of Intravenous MNK-010 in Advanced Solid Tumors
A Phase 1 study, sponsored by Mallinckrodt.
- Terminated
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
NCT02040558 is a Phase 1 study that was terminated before completion, run by Mallinckrodt. The registered enrollment target is 44 participants.
The verdict
NCT02040558, a Phase 1 study, was terminated before completion, sponsored by Mallinckrodt.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
Study Summary
This is a multicenter, open-label, dose escalation study of MNK-010 in subjects with advanced solid malignancies who have failed conventional therapy. The safety, tolerability, pharmacokinetic (PK) profile, and preliminary antitumor activity of ascending doses of MNK-010 will be evaluated in subjects with advanced solid tumors.
Interventions
- DRUG MNK-010
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2013-07 |
| Est. Completion | 2016-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02040558
The ClinicalTrials.gov registry entry for NCT02040558 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mallinckrodt, which has 69 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MNK-010 is the first listed.
NCT02040558 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02040558 about?
NCT02040558 is a clinical study titled "Trial to Study the Safety of Intravenous MNK-010 in Advanced Solid Tumors". This is a multicenter, open-label, dose escalation study of MNK-010 in subjects with advanced solid malignancies who have failed conventional therapy. The safety, tolerability, pharmacokinetic (PK) profile, and preliminary antitumor activity of ascending doses of MNK-010 will be evaluated in subject...
What is the current status of trial NCT02040558?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2013-07. Estimated completion is 2016-07.
What interventions are being tested in trial NCT02040558?
The interventions under investigation include: MNK-010 (DRUG).
Who is sponsoring clinical trial NCT02040558?
This trial is sponsored by Mallinckrodt, which has 69 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.